NCT00879086 2023-06-22
A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Participants With Advanced Breast Cancer
Eisai Inc.
Phase 2 Completed
Clinical Trials
12 trialsNCT01945710 2019-07-23
An Open-label, Multicenter, Multiple Dose, Phase 1 Study to Establish the Maximum Tolerated Dose of E7389 Liposomal Formulation in Patients With Solid Tumors
Eisai Inc.
Phase 1 Completed
NCT02171260 2019-01-15
BOLD 113
Eisai Inc.
Phase 1 Completed
NCT03002493 2017-03-15
To Assess the Effect of Rifampicin on the Pharmacokinetics of Eribulin Mesylate in Participants With Advanced Solid Tumors
Eisai Inc.
Phase 1 Completed
NCT01585870 2015-10-27
Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of Sorafenib and Eribulin in Combination
Bayer
Phase 1 Completed
NCT01000376 2013-09-23
Evaluating the Pharmacokinetics and Tolerance of Co-administration of Oral Multiple Dose of Ketoconazole and an IV (Bolus) Infusion of Eribulin in Patients With Advanced Solid Tumors
Eisai Inc.
Phase 1 Completed
NCT00965523 2013-08-15
Study of E7389 for Advanced or Metastatic Breast Cancer
Eisai Inc.
Phase 2 Completed
NCT00268905 2013-02-12
A Dose-Finding Study of E7389 in Combination With Carboplatin in Patients With Solid Tumors
Eisai Inc.
Phase 1 Completed
NCT01106248 2012-04-13
QT Interval Prolongation Study of Eribulin Mesylate (E7389) in Patients With Advanced Solid Tumors
Eisai Inc.
Phase 1 Completed
NCT00069277 2012-04-11
Study of E7389 Administered Once Every 3 Weeks In Patients With Advanced Solid Tumors
Eisai Inc.
Phase 1 Completed
NCT00706095 2012-03-27
Study Of Eribulin (E7389) In Patients With Advanced Solid Tumors And Normal Or Reduced Hepatic Function As Per Child-Pugh System
Eisai Inc.
Phase 1 Completed
NCT00069264 2011-12-20
Study of E7389 in Patients With Advanced Solid Tumors
Eisai Inc.
Phase 1 Completed